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used ICER and 2 used C/E as outcomes. Liraglutide is more cost-effective than 
sitagliptin because the ICER of liraglutide vs. sitagliptin is $25742/QALY in USA, 
£9851/QALY in England and EUR13266/QALY in Spain. All the reported ICERs were 
below the implemented country-specific thresholds. The results of 2 studies of 
exenatide vs. sitagliptin were opposite. CONCLUSIONS: Present published lit-
eratures showed GLP-1receptor agonist may be more cost-effective than DPP-4 
inhibitor. But the conclusions remain to be confirmed further by more high qual-
ity studies.
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OBJECTIVES: Develop a cost-utility assessment with diabetes mellitus type 2 
patients comparing detemir to glargine and NPH insulin in Colombia. METHODS: 
A Markov chain model was adapted to incorporate the quality life measures to 
the disease events, using the startup of NPH insulin, detemir or glargine to the 
development of macro and microvascular events or death, in a 5-year time horizon 
and for a 10.000 patients cohorts, with different levels of glycosylated hemoglobin. 
By the other hand, quality life data were derived from international research and 
used as utility measure in each event. Costs were estimated from the 2014 health 
system transactions values in Colombian pesos. Furthermore, additional parameters 
as the effectiveness information and hypoglycemic events were updated to 2014. 
The research included a Monte Carlo model for sensibility analysis and a budget 
impact analysis. RESULTS: Detemir taken at a standard daily dose of 20IU present 
less macro and microvascular events compare with other drugs. The QALYs aver-
age for determir harm were 2,60 to 2,54 using glargine and 2,53 using NPH insulin. 
The final average-cost of detemir was $ COP 88.720,67 less per patient tan glargine, 
and $ COP 75.252,50 less than NPH insulin. Detemir dominance remained through 
the probabilistic analysis. CONCLUSIONS: Under the analyzed conditions determir 
would be dominant compare to using NPH or glangine, from the QALYs viewpoint 
and in a 5-year time horizon.
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OBJECTIVES: To assess the prevalence of and predictors associated with genitou-
rinary (GU) conditions among patients with type 2 diabetes mellitus (T2DM) and 
to understand the treatment pathways patients employ when these conditions 
occur. METHODS: An internet-based survey was conducted in July 2014. The sam-
ple recruited from YouGov PollingPoint Panel in the U.S. included 2,000 adults with 
T2DM diagnosed by a physician for at least one year and treated with T2DM medica-
tions. Participants who reported a GU condition (urinary tract infection [UTI] and/or 
genital infection [GI] including genital yeast infection, bacterial vaginosis/vaginitis 
[BV], or balanitis) in the past 12 months were asked to complete survey questions 
about their GU conditions. Descriptive analysis and logistic regressions were per-
formed. RESULTS: 399 participants (20%) experienced at least one GU condition in 
the past 12 months; 309 (15.5%) reported UTI and 169 (8.5%) reported GI condition. 
The most common GI condition was yeast infection (n= 115, 5.8%). Predictors of GU 
conditions included: higher HbA1c level (i.e. 8%> HbA1c ≥ 7% vs. < 7%, OR [95% CI] 
= 1.41 [1.05, 1.90]), female vs. male (2.78 [2.16, 3.58]), and more comorbid conditions 
(i.e. 1 vs. > 5 comorbid conditions, 0.38 [0.23, 0.64]). Among respondents reporting 
GU conditions, 82.4% sought professional care. Female vs. male (2.00 [1.08, 3.70]), 
chronic vs. acute infections (2.83 [1.35, 5.94]), and more comorbid conditions (i.e. 1 
vs. > 5 comorbid conditions, 0.14 [0.04, 0.47]) were associated with higher odds of 
seeking professional care. CONCLUSIONS: In this study, 20% of participants with 
T2DM experienced GU conditions in the past 12 months, among whom 17.6% did 
not seek professional care. Predictors observed in this study could help physicians 
and health plans to identify those patients at high risk of GU conditions or those 
whose condition may potentially advance to professional care to better manage 
these conditions among the T2DM population.
DiaBetes/enDocrine DisorDers – Patient-reported outcomes & Patient 
Preference studies
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OBJECTIVES: To examine the effect of a pharmacist telephone intervention on pre-
venting medication discontinuation of ACE-Is/ARBs among non-adherent hyper-
tensive patients with diabetes enrolled in a Texas-based Medicare Advantage 
plan. METHODS: The health plan medical claims data was used to identify patients 
with hypertension and diabetes diagnoses and at least 2 fills for ACE-Is or ARBs 
between January/2013- October/2013. Patients who failed to refill their medication 
for more than one day, and had a proportion of days covered (PDC) < 0.8 were con-
sidered non-adherent and contacted by a pharmacist by phone. Multivariate logistic 
regression was conducted to assess the intervention effect on medication discontin-
uation during the 6 months post-intervention. The outcome variable was a categori-
cal variable of continuing (yes) vs discontinuation (no). Major independent variable 
hoc dataset was also the source of the background patient characteristics. Costs 
and benefits were discounted at 5% and assessed from the Canadian perspective. 
Sensitivity analyses were performed. RESULTS: Both CANA 100 and 300 mg were 
dominant compared to SAXA 5 mg (lower net cost and greater quality-adjusted 
life-years [QALYs]). CANA 100 and 300 mg reduced costs (–$375 and –$771, respec-
tively) and improved QALYs (0.033 and 0.057, respectively) over 40 years. Sensitivity 
analyses support these findings. CONCLUSIONS: These results suggest that using 
CANA in older individuals is cost-effective versus SAXA in Canada.
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OBJECTIVES: The key challenges in the successful treatment of type 2 diabetes 
include maintaining tight glycemic control, minimizing the risk of hypoglycemia, 
controlling cardiovascular risk factors, and controlling body weight. The aim of the 
present analysis was to evaluate the cost per patient achieving a composite clinical 
endpoint (HbA1c < 7%, with no weight gain and no hypoglycemic events) in patients 
with type 2 diabetes in Canada receiving liraglutide 1.2 mg, liraglutide 1.8 mg, thia-
zolidinedione, sulfonylurea, insulin glargine, sitagliptin or exenatide. METHODS: 
The proportion of patients achieving control was taken from a meta-analysis of the 
phase 3 trial program of liraglutide. Treatment costs were estimated from a health-
care payer perspective. Cost-effectiveness in terms of cost per patient achieving the 
composite endpoint (cost of control) was evaluated with an economic model devel-
oped in Microsoft Excel. No discounting was applied to cost or clinical outcomes as 
these were not projected beyond a 1-year time horizon. Sensitivity analyses were 
performed. RESULTS: Liraglutide 1.8 mg was associated with the lowest number 
needed to treat to bring one patient to the composite endpoint. Evaluation of only 
annual pharmacy costs indicated that was associated with the lowest direct annual 
costs. Combining the clinical efficacy data with the annual cost of medications 
produced cost of control values of CAD 6,070 (liraglutide 1.2 mg), CAD 6,949 (lira-
glutide 1.8 mg), CAD 7,237 (glimepiride), CAD 7,704 (exenatide), CAD 8,297 (insulin 
glargine), CAD 8,741 (pioglitazone) and CAD 9,270 (sitagliptin) per patient achiev-
ing the composite endpoint. CONCLUSIONS: Liraglutide 1.2 mg and 1.8 mg were 
associated with the lowest cost of control values, driven by the high proportion of 
patients achieving the composite endpoint. A relatively low cost of control value 
was achieved for glimepiride, driven by low acquisition costs, despite relatively few 
patients achieving the composite endpoint.
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OBJECTIVES: We determined based on the adquisition cost of the different DPP4 
inhibitors (IDDP4) in Mexico, the cost of daily treatment and performed a cost effec-
tiveness analysis having the percentage of patients with a HbA1c level less than 7% 
calculating the number needed to treat for each treatment (NNT). METHODS: Due 
that there are no head to head studies between IDPP4 therapies and with the goal of 
diminish confounding factors, we performed a search of clinical studies controlled 
with placebo in naïve patients for DPP4 therapies available in Mexico (linagliptin, 
saxagliptin, vildagliptin and sitagliptin) five studies were included. According to the 
American Asociation for the Diabetes 2011, the endpoint was determined as control 
if the patient had a HbA1c less than 7 mg/dL. The follow up time was 24 weeks. NNT 
was calculated for each therapy, in the case of vildagliptin where two studies were 
included, the results were pondered. Using the NNT we calculated the mean cost 
effectiveness ratio. RESULTS: The efficacy measured by the percentage of patients 
that reach a Hb1Ac less than 7 range from 25.3% to 42% in the IDPP4 group and from 
11.6 to 24% in the placebo group. The NNT calculated for each IDDP4 are: sitagliptin 
4.17, vildagliptin 5.48, saxagliptin 7.14 and linagliptin 7.35. The cost effectiveness 
for sitagliptin was 6,885 pesos, vildagliptin 8,503.07 pesos, saxagliptin 11,475 pesos 
and linagliptin 11,891.04 pesos. CONCLUSIONS: Sitagliptin has the less NNT of all 
IDDP4, so it may make a more efficient resource asignation. The mean cost effec-
tiveness ratio help us to interpret the real cost of the treatment analized with the 
same effectiveness measure.
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OBJECTIVES: To evaluate the pharmacoeconomic outcome of GLP-1 receptors ago-
nist vs. DPP-4 inhibitors in patients with type 2 diabetes. METHODS: A systematic 
literature search of pharmacoeconomic studies on GLP-1 receptors agonist vs. 
DPP-4 inhibitor was carried out in following databases: PubMed, Embase, Cochrane 
Library, and Chinese Knowledge Infrastructure (CNKI) (from the inception to 
April.2014). Two review authors independently applied the inclusion criteria, 
assessed trial quality, and extracted the data. The methodological qualities were 
evaluated by a scale of 26 items which developed based on 3 economic evaluation 
principles and guidelines (Drummond’s, Ramsey’s and Papaioannou’s) , and the 
data were analyzed using descriptive analysis. RESULTS: According to the inclu-
sion and exclusion criteria 6 randomized controlled clinical trials and modeling 
studies were selected, including 4 studies of liraglutide+ metformin vs. sitagliptin+ 
metformin, 1 study of exenatide+ metformin vs. sitagliptin + metformin, and 1 
study of exenatide vs. sitagliptin. The methodological quality of them were scored 
19-24(total score was 26). There were 5 CUA studies which conducted a long-term 
simulation ≥ 35 years using CDM model, and 1 short-term CEA study. 4 studies 
